1. Expression of dengue capsid-like particles in silkworm and display of envelope domain III of dengue virus serotype 2.
- Author
-
Muthuraman KR, Utomo DIS, Matsuda M, Suzuki R, and Park EY
- Subjects
- Animals, Mice, Capsid Proteins genetics, Capsid Proteins immunology, Capsid Proteins chemistry, Capsid Proteins biosynthesis, Dengue Vaccines immunology, Dengue Vaccines genetics, Antibodies, Viral immunology, Dengue immunology, Dengue virology, Serogroup, Protein Domains, Female, Bombyx genetics, Bombyx virology, Bombyx metabolism, Dengue Virus genetics, Dengue Virus immunology, Mice, Inbred BALB C, Viral Envelope Proteins genetics, Viral Envelope Proteins immunology, Viral Envelope Proteins chemistry, Viral Envelope Proteins biosynthesis, Antibodies, Neutralizing immunology
- Abstract
Dengue virus (DENV) is a considerable public health threat affecting millions of people globally. Vaccines for dengue are an important strategy to reduce the disease burden. We expressed capsid (C2) and envelope domain III of dengue virus serotype 2 (2EDIII) separately in the silkworm expression system. We conjugated them employing the monomeric streptavidin (mSA2) and biotin affinity to display the antigenic 2EDIII on the C2-forming capsid-like particle (CLP). Purified 2EDIII-displaying C2 (CLP/2EDIII) was immunogenic in BALB/c mice, eliciting neutralizing antibodies confirmed by a single-round infectious particle (SRIP) neutralization assay. Th1 cytokine levels were upregulated for the CLP/2EDIII group, and the anti-inflammatory IL-10 and pro-inflammatory IL-6 cytokine levels were also raised compared to the 2EDIII and the control groups. Elevated cytokine levels for CLP/2EDIII indicate the importance of displaying the 2EDIII as CLP/2EDIII rather than as an individual subunit. This study is the first to express the C2 protein as self-assembling CLP in vivo and 2EDIII separately in the silkworm expression system and conjugate them to form a monovalent CLP. Thus, this CLP/2EDIII display method may pave the way for an efficient tetravalent dengue vaccine candidate., Competing Interests: Declaration of competing interest All the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF